Nome |
# |
Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs, file e3835327-8179-15e8-e053-a505fe0a3de9
|
262
|
Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET/CT in the management of GEP-NENs. a systematic review, file e3835324-db0b-15e8-e053-a505fe0a3de9
|
118
|
Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center, file e3835324-7b5a-15e8-e053-a505fe0a3de9
|
73
|
Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia. A systematic review, file e383532e-13da-15e8-e053-a505fe0a3de9
|
64
|
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs. A Multicenter Study, file e3835326-648b-15e8-e053-a505fe0a3de9
|
58
|
Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia. A Systematic Review, file e383532b-44c8-15e8-e053-a505fe0a3de9
|
49
|
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors, file e383532e-2e5d-15e8-e053-a505fe0a3de9
|
38
|
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors, file 4a1bf835-4ca2-4f4f-94ec-a712be75a12d
|
33
|
Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia. A Case Series, file e383532e-c202-15e8-e053-a505fe0a3de9
|
30
|
Tumor heterogenity in gastro-entero-pancreatic neuroendocrine neoplasia, file e383532e-295a-15e8-e053-a505fe0a3de9
|
22
|
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms. The NOVARA Score, a Multicentre Retrospective Study, file e383532e-64e6-15e8-e053-a505fe0a3de9
|
21
|
Prognostic significance of laterality in lung neuroendocrine tumors, file e383532e-d5ac-15e8-e053-a505fe0a3de9
|
20
|
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet), file e383532e-64e9-15e8-e053-a505fe0a3de9
|
19
|
Management of functional pancreatic neuroendocrine neoplasms, file 7a681ba3-e872-4d89-b6ab-2aca5e1a5c11
|
17
|
Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia, file a254f032-909e-49e2-aca1-e62aa7fc749b
|
17
|
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm. Study Protocol for a Prospective Observational Study, file e383532e-68c7-15e8-e053-a505fe0a3de9
|
17
|
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors, file e383532e-c190-15e8-e053-a505fe0a3de9
|
17
|
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastro entero pancreatic neuroendocrine tumors. alternatives to RECIST, file 8d97f0a4-9c33-4764-bd43-eef3797a4692
|
16
|
Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients., file e3835319-be25-15e8-e053-a505fe0a3de9
|
16
|
Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors. Answers and Unsolved Problems, file e383532e-64ea-15e8-e053-a505fe0a3de9
|
16
|
What gastroenterologists should know about carcinoid syndrome, file f0effa91-3d5c-46e3-b217-cb69d8415e43
|
16
|
Stage IV gastro-entero-pancreatic neuroendocrine neoplasms. A risk score to predict clinical outcome, file e383532e-bc7e-15e8-e053-a505fe0a3de9
|
14
|
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors. A Systematic Review and Meta-Analysis, file 9afa2295-18bf-444a-885e-b5d7973a615e
|
12
|
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm. interim analysis of prospective ASPEN trial, file b8a3bffd-e01b-4b4d-b604-e5e91c537f92
|
12
|
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors, file e383532e-6796-15e8-e053-a505fe0a3de9
|
12
|
Therapy for Locoregional Disease. Stomach/Duodenum, Colon/Rectum, file b461e204-33bf-44c7-8a1d-3498d403091b
|
8
|
Controversies in the treatment of digestive neuroendocrine tumors, file 203f0c1b-d44d-45e5-8bc9-55dfa0f4c9df
|
7
|
Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function, file 88934104-a7f0-4c54-a505-117bbe95244c
|
7
|
CT texture analysis of liver metastases in PNETs versus NPNETs. correlation with histopathological findings, file e3835325-36bb-15e8-e053-a505fe0a3de9
|
6
|
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations, file e3835326-8efe-15e8-e053-a505fe0a3de9
|
6
|
Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms. Data from a large international cohort study, file e383532e-be20-15e8-e053-a505fe0a3de9
|
6
|
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size. a retrospective, Europe-wide, pooled cohort study, file 0881cb86-c014-4ffb-8e37-044a4634a71e
|
5
|
Treatment of Intestinal NETs (Including Appendix), file 118a5113-8bfa-4330-aaf2-4b6fa0d0abec
|
5
|
A case of pancreatic small cell neuroendocrine carcinoma associated with SIADH, file e383532a-e5a0-15e8-e053-a505fe0a3de9
|
5
|
Sporadic non-functioning pancreatic neuroendocrine tumours. multicentre analysis, file e383532e-5e0e-15e8-e053-a505fe0a3de9
|
5
|
[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia, file e3835327-cb7e-15e8-e053-a505fe0a3de9
|
4
|
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia, file e383532e-279d-15e8-e053-a505fe0a3de9
|
4
|
Targeting neuroendocrine tumors with octreotide and lanreotide. Key points for clinical practice from NET specialists, file 2af9320f-970b-4442-8d79-a396eff322be
|
3
|
Therapy for Locoregional Disease. Stomach/Duodenum, Colon/Rectum, file a136f93b-05ee-429d-b039-491001856edd
|
3
|
Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms, file e3835317-d8fd-15e8-e053-a505fe0a3de9
|
3
|
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia. a multicentre retrospective study, file e3835326-7a17-15e8-e053-a505fe0a3de9
|
3
|
Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms, file e3835328-985c-15e8-e053-a505fe0a3de9
|
3
|
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. A Multicentric Retrospective Study, file e383532c-339d-15e8-e053-a505fe0a3de9
|
3
|
Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response, file e383532e-4798-15e8-e053-a505fe0a3de9
|
3
|
The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs, file e383532e-7829-15e8-e053-a505fe0a3de9
|
3
|
Treatment of Intestinal NETs (Including Appendix), file f6abb801-e35d-4bc4-9aeb-e8665a034f40
|
3
|
New Prognostic Frontiers for Lung Neuroendocrine Tumors, file 308e00a6-4e1f-4ee9-a871-888bc871372f
|
2
|
MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells, file afe32c9c-7e55-42e3-8b79-0bde02014274
|
2
|
[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia, file e383532a-8914-15e8-e053-a505fe0a3de9
|
2
|
Everolimus in pancreatic neuroendocrine carcinomas G3, file e383532e-6d5b-15e8-e053-a505fe0a3de9
|
2
|
Risk of preoperative understaging of duodenal neuroendocrine neoplasms. a plea for caution in the treatment strategy, file e383532e-a468-15e8-e053-a505fe0a3de9
|
2
|
Gastro-entero-pancreatic neuroendocrine neoplasia. The rules for non-operative management, file e383532f-37b2-15e8-e053-a505fe0a3de9
|
2
|
Type 3 gastric neuroendocrine neoplasms: the rising promise of conservative endoscopic management, file 584cb084-ab4b-4fb2-a86e-adc867f6d9d2
|
1
|
Management of type-I gastric neuroendocrine neoplasms. A 10-years prospective single centre study, file b7739403-c01c-4060-93e4-bd0d4004d981
|
1
|
The role of combined Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors, file e3835313-1ddd-15e8-e053-a505fe0a3de9
|
1
|
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. A Multicentric Retrospective Study, file e383532c-1e81-15e8-e053-a505fe0a3de9
|
1
|
Reply to Dr. Hall and coworkers, file e383532e-64ed-15e8-e053-a505fe0a3de9
|
1
|
Bone Metastases in Neuroendocrine Tumors. Molecular Pathogenesis and Implications in Clinical Practice, file e383532e-68cf-15e8-e053-a505fe0a3de9
|
1
|
Totale |
1.102 |